Litcius/Paper detail

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal‐Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Marta Casarrubios, Clara Salas, Edwin R. Parra, Ignacio I. Wistuba, Virginia Calvo, Raquel Laza‐Briviesca, Atocha Romero, Bartomeu Massutí, Alberto Cruz‐Bermúdez

2020The Lancet Oncology829 citationsDOI

Topics & Concepts

NivolumabMedicineOpen labelChemotherapyOncologyLung cancerInternal medicineNeoadjuvant therapyPhases of clinical researchCancerClinical trialImmunotherapyBreast cancerLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial | Litcius